Physician profile
Michael Jon Bode
NPI 1689669640
$9,251.33
in general payments reported to CMS, 2019-2025
44 companies · $1,229 in 2025
The $1,229 reported for 2025 was more than what 89% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,475 · 2020: $998 · 2021: $1,715 · 2022: $994 · 2023: $1,315 · 2024: $1,525 · 2025: $1,229.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,069.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,069.28 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $1,422.31 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Pfizer INC. | $872.05 | 2019-2025 | |
| Astrazeneca Pharmaceuticals Lp | $862.44 | 2019-2025 | Airsupra, Farxiga, Breztri |
| Lilly USA, LLC | $742.63 | 2019-2025 | Mounjaro, Zepbound, Jardiance |
| Abbvie INC. | $676.43 | 2021-2025 | Vraylar, Ubrelvy |
| Glaxosmithkline, LLC. | $673.66 | 2019-2025 | Trelegy Ellipta, Arexvy, Shingrix |
| Boehringer Ingelheim Pharmaceuticals, INC. | $357.41 | 2019-2024 | Jardiance |
| Novartis Pharmaceuticals Corporation | $344.63 | 2019-2025 | |
| Amgen INC. | $331.02 | 2019-2025 | Otezla, Repatha, Otezla |
| Astellas Pharma US INC | $310.01 | 2019-2025 | Veozah, Myrbetriq |
| Janssen Pharmaceuticals, INC | $304.96 | 2019-2023 | Xarelto |
| Bayer Healthcare Pharmaceuticals INC. | $234.73 | 2021-2025 | |
| Abbott Laboratories | $154.40 | 2021-2024 | Ensite |
| Merck Sharp & Dohme LLC | $144.09 | 2019-2024 | Capvaxive, Gardasil 9, Gardasil |
| Takeda Pharmaceuticals U.S.A., INC. | $139.23 | 2019-2022 |
Show all 44 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Michael Bode listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.